Stephen Feider Sells 5,104 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 5,104 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $17.05, for a total transaction of $87,023.20. Following the completion of the sale, the chief financial officer owned 165,931 shares in the company, valued at $2,829,123.55. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total value of $84,184.36.

Beta Bionics Price Performance

Beta Bionics stock opened at $16.70 on Thursday. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The stock has a market cap of $744.15 million, a PE ratio of -11.06 and a beta of 3.02. The stock’s fifty day moving average is $12.36 and its two-hundred day moving average is $15.22.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The company had revenue of $27.63 million during the quarter. On average, research analysts expect that Beta Bionics, Inc. will post -2.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Bank of America reduced their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Weiss Ratings cut Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Leerink Partners cut their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Finally, Stifel Nicolaus decreased their price objective on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average target price of $19.70.

Hedge Funds Weigh In On Beta Bionics

A number of large investors have recently bought and sold shares of BBNX. Perceptive Advisors LLC raised its holdings in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares in the last quarter. Eversept Partners LP lifted its holdings in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Beta Bionics by 112.9% in the first quarter. Quantinno Capital Management LP now owns 67,879 shares of the company’s stock valued at $680,000 after purchasing an additional 35,996 shares during the period. Lazard Asset Management LLC purchased a new position in Beta Bionics in the first quarter valued at about $720,000. Finally, Granahan Investment Management LLC grew its holdings in shares of Beta Bionics by 104.9% in the 1st quarter. Granahan Investment Management LLC now owns 248,449 shares of the company’s stock worth $2,489,000 after acquiring an additional 127,203 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.